The Adapt Oculus trial is unique in that it includes a patient population often overlooked in clinical trials, patients presenting with ocular myasthenia gravis (MG).

X recently announced results from additional analyses of its blockbuster FcRn inhibitor Vyvgart in the phase III Adapt Oculus study. The study evaluated the efficacy and safety of Vyvgart administered ...

More than 60% of complement inhibitor–naive patients with acetylcholine receptor–positive generalized myasthenia gravis (MG) in diverse clinical populations had a clinically meaningful reduction in MG ...

Variants in a nicotine receptor gene are associated with a lower likelihood of heavy smoking, according to a study published ...

They discovered that these antibodies can disrupt the normal receptor functioning in a variety of ways. Certain antibodies block the regular acetylcholine binding process, the researchers found, while ...

In a serendipitous discovery, UC San Diego researchers using cryo-EM technology captured the first visualizations of the 3-D structure of the muscle acetylcholine receptor in fetal and adult muscles.

In healthy people, binding of the molecule acetylcholine (ACh) to its receptor (AChR) on skeletal muscle cells triggers muscle contraction underlying regular daily activities. In the autoimmune ...